Suzy A Griffin Selected Research

1- ((5- methoxy- 1H- indol- 3- yl)methyl)- 4- (4- (methylthio)phenyl)piperidin- 4- ol

1/2013

The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Suzy A Griffin Research Topics

Disease

4	Dyskinesias (Dyskinesia) 05/2021 - 05/2009
4	Parkinson Disease (Parkinson's Disease) 05/2021 - 05/2009
1	Substance-Related Disorders (Drug Abuse) 01/2019
1	Movement Disorders (Movement Disorder) 01/2013

Drug/Important Bio-Agent (IBA)

6	Dopamine Receptors (Dopamine Receptor)IBA 05/2021 - 05/2009
4	Levodopa (L Dopa)FDA LinkGeneric 05/2021 - 05/2009
2	LigandsIBA 05/2021 - 01/2019
2	Oxidopamine (6 Hydroxydopamine)IBA 05/2021 - 05/2009
2	N- (4- (4- (2,3- dichlorophenyl)piperazin- 1- yl)but- 2- enyl)- 4- pyridine- 2- ylbenzamideIBA 02/2011 - 05/2009
2	SK&F 81297IBA 05/2009 - 05/2009
1	1- ((5- methoxy- 1H- indol- 3- yl)methyl)- 4- (4- (methylthio)phenyl)piperidin- 4- olIBA 01/2013
1	Adenylyl Cyclases (Adenylyl Cyclase)IBA 02/2011
1	N- (4- (4- (2,3- dichlorophenyl)piperazin- 1- yl)butyl)- 4- (pyridin- 3- yl)benzamideIBA 02/2011
1	Dopamine Agonists (Dopamine Agonist)IBA 05/2009
1	phenylpiperazineIBA 05/2009
1	Bromocriptine (Parlodel)FDA LinkGeneric 05/2009

Therapy/Procedure

1	Therapeutics 01/2019